- Conditions
- Heart Failure Preserved Ejection Fraction
- Interventions
- Resistance Exercise Training, DEXA bone scan, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, Submaximal Exercise Test, Blood Draw
- Other · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 140
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction
- Interventions
- LY3540378, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Covina, California • Northridge, California + 18 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- AZD4831, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 21
- States / cities
- Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
- Conditions
- Pulmonary Hypertension Secondary, Heart Failure
- Interventions
- Sodium Nitrite, Placebo Oral Capsule
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- HFpEF
- Interventions
- Exercise training
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Heart Failure With Preserved Ejection Fraction, Obesity
- Interventions
- HeO2 gas mixture, Room air gas mixture
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Iron-deficiency, Heart Failure With Preserved Ejection Fraction
- Interventions
- Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- AZD4831, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Heart Failure, Congestive Heart Failure
- Interventions
- Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine, Placebo
- Drug
- Lead sponsor
- Corporal Michael J. Crescenz VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
- Interventions
- MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
- Drug
- Lead sponsor
- Horng Chen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal), Persistent Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- progressive resistance training, combined aerobic + resistance training
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- STM01
- Drug
- Lead sponsor
- Secretome Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Dallas, Texas
- Conditions
- Type 2 Diabetes, Heart Failure
- Interventions
- Oral semaglutide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
- Interventions
- Exogenous Ketone Drink, Placebo
- Dietary Supplement
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Sotagliflozin, Placebo
- Drug
- Lead sponsor
- Juan Badimon
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
- Interventions
- Scintigraphy
- Diagnostic Test
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 22
- States / cities
- Fairhope, Alabama • Huntsville, Alabama • Miami, Florida + 11 more
- Conditions
- Diastolic Heart Failure, Hypertensive Heart Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Oxidative Stress
- Interventions
- grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 16 more
- Conditions
- Heart Failure
- Interventions
- AZD4831, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 39 more
- Conditions
- Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- Interventions
- Oral treprostinil, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
- Conditions
- Heart Failure With Preserved Ejection Fraction, Inflammation
- Interventions
- L-Citrulline, Placebo for L-Citrulline, BH4, Placebo for BH4, Atorvastatin, Placebo for Atorvastatin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 87
- States / cities
- Irvine, California • Long Beach, California • Los Angeles, California + 77 more